Visit Torray U.S. Mutual Fund

You are leaving Torray Investment Partners

You are now leaving the Torray Investment Partners website and being redirected to the Torray Fund website.

Continue

Literature

Strategies

Quarterly Commentary

Concentrated Large Growth

Small/Mid Cap Growth

Large Value Equity

Equity Income

News and Insights

Bob Torray's Lasting Impact

CNBC Article featuring The Torray Fund

Under Appreciated Value in Biotech

June 2024

Quarterly Commentary

Small/Mid Cap Growth Quarterly Commentary

Selectivity and active management in the SMID-cap universe is key. For over 17 years, the Torray SMID Growth Strategy has, in general, outperformed over full-market cycles, experienced less dramatic drawdowns in stressful periods, and delivered an attractive risk-adjusted return stream.

March 2024

Value Investor Insight

Under Appreciated Value in Biotech

Royalty Treatment. Royalty Pharma wants to benefit from the high-risk, high-return innovation in the pharmaceutical industry without bearing all the risks. Torray Investments' Shawn Hendon thinks the firm deserves more credit for doing that well.

July 2023

Report

25th Anniversary of Torray Concentrated Large Growth Strategy

For 25 Years, we have passionately believed a thoughtfully constructed, concentrated portfolio of businesses with attractive risk-adjusted growth characteristics can add value for clients over the long term.

February 2023

Press Release

Long-Tenured Fund Reboots with Reorganization; Hires Distribution Specialist

Torray Investment Partners (“Torray”), an employee-owned investment advisor specializing in concentrated, low turnover growth- and value-oriented strategies, is proud to announce the reorganization of its flagship fund, The Torray Fund, (Ticker: TORYX) into The RBB Fund Trust (“RBB”).

You are leaving Torray Investment Partners

You are now leaving the Torray Investment Partners website and being redirected to the Torray Fund website.

Continue